PCG Digital: Soligenix Anticipated to Achieve Multiple Milestones in 2021
New York, New York (Newsfile Corp. - March 16, 2021) - PCG Digital The future is looking bright at Soligenix, Inc. In a corporate update released on February 24
th, Dr. Christopher Schaber, Chairman, President and CEO, updated investors on the status of ongoing research projects. The report suggests that multiple milestones will be achieved this year and next.
One of the key corporate highlights is the completion of a Phase 3 FLASH ( Fluorescent Light Activated Synthetic Hypericin ) study with SGX301 (synthetic hypericin), a treatment for cutaneous T-cell lymphoma (CTCL). Pending FDA clearance, the treatment will be marketed as HyBryte.
Axcend Awarded a Phase II SBIR Grant from the National Institutes of Health
Share Article
This Phase II SBIR Grant continues successful Phase I research by Axcend to develop a “Portable Liquid Chromatography Platform for Diverse Pharmaceutical Applications”
The Axcend Focus LC, Axcend s hand-portable, lightweight and compact capillary high-performance liquid chromatography (HPLC) system
We are honored to receive this Phase II SBIR grant and look forward to successfully developing and commercializing compact HPLC for pharmaceutical applications. PROVO, Utah (PRWEB) March 04, 2021
Axcend® today announced that it has been awarded a Phase II SBIR Grant to continue its work in developing a “Portable Liquid Chromatography Platform for Diverse Pharmaceutical Applications.”
March 3, 2021 |
Biomedical Engineering
Using nanoparticles to deliver drugs directly to tumors is a novel technology developed by NanoMedTrix, LLC, a UI spin-off founded by Jose Assouline, an adjunct associate professor in the Roy J. Carver Department of Biomedical Engineering and the Roy J. and Lucille A. Carver College of Medicine. The targeted delivery of these nanoparticles to treat diseases such as bladder cancer has led to a two-year, $2 million Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute.
“Not only do these nanoparticles bind to tumors for treatment, but they also provide imaging of the tumors which we can then analyze,” said Assouline. “These valuable images computed remotely, which has appreciable clinical usefulness during the pandemic when we are working to limit close-contact interactions.”
Soligenix Provides Important Highlights and Upcoming Catalysts in Corporate Update Letter
News provided by
Share this article
Share this article
PRINCETON, N.J., Feb. 24, 2021 /PRNewswire/ Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber. The content of this letter is provided below.
Dear Friends and Shareholders,
I would like to start by thanking you for your continued support, and hope that you and your families are all healthy and well. As 2020 recedes in the rearview mirror, we seem to be turning a corner on the challenges the COVID-19 pandemic has imposed on our everyday lives with promising coronavirus vaccines and a hope to return to a more normal existence in the not too distant future. Hope and rec
Greensea Receives US Navy Award
Maritime Activity Reports, Inc. January 21, 2021
“The long range standoff command and control of ROVs is the single best solution to keep the warfighter safe by getting them as far as possible from a subsea threat,” said Ben Kinnaman, CEO of Greensea.
Greensea s open architecture technology on Remotely Operated Vehicles furthered by Small Business Innovation Research Phase II grant
Greensea Systems, Inc. creator of OPENSEA, an open architecture robotics platform for the marine industry, won a Phase II Small Business Innovation Research (SBIR) ASAP grant totaling $1,100,000, with option for additional funding, for the continued development of Standoff Command and Control of Remotely Operated Vehicles (ROVs). This project has been funded in whole or in part with Federal funds from the Naval Air Warfare Center Aircraft Division, under Contract No. N6833521C0113.